AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- David Silverstone, M.D.
-
-
Georgia
-
Roswell, Georgia, États-Unis, 30076
- Coastal Research Associates, LLC
-
-
Kansas
-
Shawnee Mission, Kansas, États-Unis, 66204
- Heart of America Eye Care, P.A.
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40217
- Taustine Eye Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21209
- Alan L Robin, M.D.
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63090
- Comprehensive Eye Care
-
-
New York
-
Rochester, New York, États-Unis, 14618
- Rochester Ophthalmology Group
-
Slingerlands, New York, États-Unis, 12159
- Glaucoma Consultants of the Capital Region
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28210
- Charlotte Eye Ear Nose and Throat
-
Charlotte, North Carolina, États-Unis, 28204
- Thomas K. Mundorf, M.D.
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis, 74104
- The Eye Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Wills Eye Hospital
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
El Paso, Texas, États-Unis, 79902
- Cataract & Glaucoma Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84117
- Stacy R. Smith, M.D.
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 years of age or greater.
- Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Currently using prostaglandin analogue (monotherapy or combination therapy) O.U. ≥ 1 month at time of study entry (first qualification visit) in study eye(s).
- Qualification Visit 1 (Screening) IOP at 16:00 hrs: PG monotherapy patients: ≥ 18 mm Hg; Combination therapy patients: >= 16 mm Hg. Qualification Visit 2 (post latanoprost run-in) IOP ≥ 20 mm Hg at 08:00 hrs and 10:00 hrs, IOP ≥ 18 mm Hg at 16:00 hrs in study eye(s). (Note: combination therapy may include any combination of topical ocular hypotensive agents).
- Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- Able and willing to give signed informed consent and follow study instructions
Exclusion Criteria:
In either eye:
- Previously randomized to treatment in a clinical study of AR-12286.
- Intraocular pressure > 36 mm Hg.
- History of acute angle-closure glaucoma, or closed or narrow angle upon gonioscopy
- Known hypersensitivity or contraindication to timolol maleate ophthalmic solution, or any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics, including history of conjunctival hyperemia with topical latanoprost of severity greater than 1 on a 0-3 scale.
- Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
- Contact lens wear within 30 minutes of instillation of study medication.
- PG monotherapy patients: Ocular hypotensive medication (other than prostaglandin) within 4 weeks of Visit 0 (Study entry, first qualification visit). Combination therapy patients: Ocular hypotensive medication (other than prostaglandin and current additional agent) within 4 weeks of Visit 0 (Study entry, first qualification visit).
- Conjunctival hyperemia of grade 2+ or greater at Visit 1.
- Any other ocular medication within 4 weeks of Visit 1 with the exception of lubricating drops for dry eye (which may be used throughout the study).
- Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that treatment with only latanoprost for two periods of up to 4 weeks is not judged safe (e.g., advanced glaucomatous optic nerve head or visual field loss).
- Any abnormality preventing reliable applanation tonometry of either eye.
In study eye(s):
- Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure. Note: Previous laser peripheral iridotomy is acceptable.
- Previous glaucoma intraocular surgery or laser procedures.
- Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
- Central corneal thickness greater than 600 µ.
Systemic:
- Known bronchial asthma (history or current), severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block or overt cardiac failure.
- Clinically significant abnormalities in laboratory tests at screening, recognizing that subjects are not fasting at the time of drawing blood.
- Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
- Participation in any investigational study within the past 30 days.
- Changes of systemic medication that could have a substantial effect on IOP 4 weeks prior to screening, or anticipated during the study.
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: AR-12286
AR-12286 Ophthalmic Solution 0.5%
|
q.d.
Autres noms:
|
|
Comparateur actif: Timolol
Timolol maleate ophthalmic solution 0.5%
|
q.d.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intraocular pressure
Délai: 28 days
|
The primary efficacy endpoint will be the mean IOP across subjects within treatment group at each study visit at each post-treatment timepoint.
|
28 days
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ocular safety
Délai: 28 days
|
Safety endpoints will be visual acuity, objective biomicroscopic and ophthalmoscopic examination, and subjective comfort as measured by adverse events in response to subject symptom queries.
|
28 days
|
|
Systemic safety
Délai: 28 days
|
Heart rate, and blood pressure.
|
28 days
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies oculaires
- Glaucome
- Hypertension oculaire
- Hypertension
- Effets physiologiques des médicaments
- Bêta-antagonistes adrénergiques
- Antagonistes adrénergiques
- Agents adrénergiques
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-arythmie
- Agents antihypertenseurs
- Timolol
- Solutions ophtalmiques
- Solutions pharmaceutiques
- Latanoprost
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- AR-12286-CS203
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .